Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023;142(10):878-886.

On page 878, the byline omits an author, Sairah Ahmed. The byline and author affiliations should read as follows:

Philippe Armand,¹ Pier Luigi Zinzani,^2,3 Hun Ju Lee,⁴ Nathalie A. Johnson,⁵ Pauline Brice,⁶ John Radford,⁷ Vincent Ribrag,⁸ Daniel Molin,⁹ Theodoros P. Vassilakopoulos,¹⁰ Akihiro Tomita,¹¹ Bastian von Tresckow,^12,13 Margaret A. Shipp,¹ Alex F. Herrera,¹⁴ Jianxin Lin,¹⁵ Eunhee Kim,¹⁵ Samhita Chakraborty,¹⁵ Patricia Marinello,¹⁵ Sairah Ahmed,⁴ and Craig H. Moskowitz¹⁶

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; ²Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna, Italy; ³Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy; ⁴Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁵Department of Medicine, Jewish General Hospital, Montreal, QC, Canada; ⁶Hémato-Oncologie, Hôpital Saint-Louis, Paris, France; ⁷Department of Medical Oncology, NIHR Clinical Research Facility, Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; ⁸Early Drug Department (DITEP), Gustave Roussy, Villejuif, France; ⁹Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; ¹⁰Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece; ¹¹Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan; ¹²Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany; ¹³Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ¹⁴Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; ¹⁵Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ; and ¹⁶Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

On page 885, the authorship contribution statement should include the information that Sairah Ahmed contributed to acquisition of the data and critically reviewing the manuscript. The conflict-of-interest disclosure paragraph should include the following: “S.A. reports research support to her institution for clinical trials from Nektar, Merck, Xencor, Chimagen, and Genmab; consulting fees from ADC Therapeutics and Kite/Gilead; membership on a scientific advisory committee for Chimagen; and serving on a data safety monitoring board for Myeloid Therapeutics.” The ORCID profile paragraph should include the following: “S.A., 0000-0001-7302-8299.”